Clinical Study

Tumor-Agnostic Precision Immunooncology And Somatic Targeting Rational For You (Tapistry) Phase II Platform Trial

Posted Date: May 5, 2021

  • Investigator: Davendra Sohal
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.


Histologically Or Cytologically Confirmed Diagnosis Of Advanced And Unresectable Or Metastatic Solid Malignancy, Life Expectancy >= 8 Weeks, Disease Progression On Prior Treatment, Or Previously Untreated Disease With No Available Acceptable Treatment, Ecog 0-2, No Anticancer Treatment Within 2 Weeks, No History Of Or Concurrent Serious Medical Condition Or Abnormality In Clinical Laboratory Tests That, In The Investigator's Judgment, Precludes The Participant's Safe Participation In And Completion Of The Study Or Confounds The Ability To Interpret Data From The Study, No Other Malignancy Within 5 Years


Phase Ii, Immunooncology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.